2012 Update

• DOI: 10.1097/aci.0b013e328355b7e4
• Publication Date: 2012-06-29T12:21:45Z
• Authors: F. Estelle R. Simons; Ledit R.F. Ardusso; M. Beatrice Bilò; Vesselin Dimov; Motohiro Ebisawa; Yehia M. El-Gamal; Dennis K. Ledford; Richard F. Lockey; Johannes Ring; Mario Sanchez-Borges; Gian Enrico Senna; Aziz Sheikh; Bernard Y. Thong; Margitta Worm
• Keywords: Male; Epinephrine; Venoms; Allergens; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Risk Factors; Humans; Vasoconstrictor Agents; Female; Prospective Studies; Anaphylaxis

Purpose of review The World Allergy Organization (WAO) Guidelines for the assessment and management anaphylaxis published in early 2011 provide a global perspective on patient risk factors, triggers, clinical diagnosis, treatment, prevention anaphylaxis. In this 2012 Update, subsequently published, clinically relevant research these areas is reviewed. Recent findings Patient factors co-factors that amplify have been documented prospective studies. triggers has expanded. criteria diagnosis are promulgated validated. Some aspects treatment prospectively studied. Novel investigations self-injectable epinephrine recurrences community performed. Progress made with regard to measurement specific IgE allergen components (component-resolved testing) might help distinguish future anaphylactic episodes an from asymptomatic sensitization allergen. New strategies immune modulation prevent food-induced new insights into subcutaneous immunotherapy venom-induced described. Summary Research highlighted Update strengthens evidence-based recommendations assessment, management, WAO Anaphylaxis Guidelines.